Pandemic prevention is the organization and management of preventive measures against pandemics. Those include measures to reduce causes of new infectious diseases and measures to prevent outbreaks and epidemics from becoming pandemics. It is not to be mistaken for pandemic preparedness or mitigation (e.g. against COVID-19) which largely seek to mitigate the magnitude of negative effects of pandemics, although the topics may overlap with pandemic prevention in some respects.
Pandemics typically arise naturally from interactions between humans and animals, but emerging technologies are also expected to facilitate the synthesis and enhancement of dangerous pathogens, making bioterrorism and laboratory accidents emerging threats.
Pandemic prevention measures include early detection systems, international coordination with information sharing, laboratory biosafety protocols, oversight of gain-of-function research, restricting access to dual-use biotechnology, monitoring spillover risks in wild animal populations, regulating wildlife trade and wet markets, reducing intensive animal farming, protecting ecosystems, and strengthening public health care systems.
In May 2025, all Member States of the World Health Organization (WHO) formally adopted the world's first Pandemic Agreement.
Measures Infrastructure and international development Robust, collaborating public health systems that have the capacity for active surveillance for early detection of cases and to mobilize their health care coordination capacity may be required to be able stop contagion promptly. After an outbreak there is a certain window of time during which a pandemic can still be stopped by the competent authorities isolating the first infected and/or fighting the pathogen. A good global infrastructure, consequent information exchange, minimal delays due to bureaucracy and effective, targeted treatment measures can be prepared. In 2012 it has been proposed to consider pandemic prevention as an aspect of international development in terms of health-care infrastructure and changes to the pathogen-related dynamics between humans and their environment including animals. Often local authority carers or doctors in Africa, Asia or Latin America register uncommon accumulations (or clusterings) of symptoms but lack options for more detailed investigations. Scientists state that "research relevant to countries with weaker surveillance, lab facilities and health systems should be prioritized" and that "in those regions, vaccine supply routes should not rely on refrigeration, and diagnostics should be available at the point of care". Two researchers have suggested that public health systems "in each country" need to be capable of detecting contagion early, diagnosing it accurately, implementing effective disease control measures, and fully collaborating with the relevant international authorities at each stage . U.S. officials have proposed a range of reforms to international health regulations and global institutions for global health security. The "entire architecture of the response to epidemics" may need to get adapted, evolving "from crisis response during discrete outbreaks to an integrated cycle of preparation, response and recovery" .
Technology-centric measures
Biosafety technologies and biotechnology regulation
Potential policies that support global biosafety could make use of various technologies, including but not limited to laboratory containment technologies – for example, tools could promote compliance with existing and novel biosecurity norms and standards. Proposals to increase biosafety in terms of laboratories, scientific field work and research and development-related activities include: limiting research on highly contagious biological agents to only trained researchers in well-protected environments and advanced biological safety systems and disposal of biohazards. improving physical security and educating scientists about the misuse potentials review processes for gain-of-function research involving enhanced potential pandemic pathogens. While such research can help develop vaccines and therapeutics preemptively, it requires careful risk assessment and safety protocols to minimize potential hazards. monitoring and strengthening laboratory protocols around the world Work on coronaviruses at the Wuhan Institute of Virology was carried out at biosafety level 2 with level 4 being the most secure. Level 3 containment is now recommended for SARS-CoV-2. As of 2020, the CDC and other health agencies recommended handling non-SARS non-MERS human coronaviruses and SARS-related coronaviruses from wild animals at Biosafety Level 2 in vitro and Level 3 in vivo. According to a study of Indian BSL-2 and BSL-3 facilities, "there are no national guidelines or reference standards available in India on certification and validation of biosafety laboratories" In a 2018 study it was suggested that there is a need "to update international laboratory biosafety guidance" "to globalize biosafety" In the wake of the COVID-19 pandemic there was a "global surge in labs that handle dangerous pathogens" and as of 2022 some researchers "are concerned about [these]". monitoring and strengthening field work protocols around the world (such as viral sampling) A small survey reported that many biosafety professionals conducting field collection of potentially infectious specimens have not been formally trained on the topic. There are multiple known examples of field-associated infections. making deadly viruses harder to engineer oversight of high-risk pathogen research measures that don't rely on relevant technological equipment and biotechnology products (as well as data and knowledge) only being available to registered scientists and all of these scientists to act responsibly may also be possible According to one expert, the "international bioweapons community" should work towards having supply chain choke points identified and help implement robust monitoring of them, such as, for example, key input material One international team plans to make DNA synthesis screening available for free to countries worldwide and could establish a level of safety if regulations require that DNA synthesis companies send sequences for screening against a certified database Only "approximately 80 percent of DNA providers are members of the International Gene Synthesis Consortium, which screens customers and DNA order sequences to prevent the building blocks of dangerous pathogens from falling into the hands of malicious actors". Screening is "costly, time-consuming, and requires human expertise", e.g. making non-participation economically beneficial. Reducing risks from methods that "may enable the creation of (or expand access to) particularly dangerous engineered pathogens" may involve careful regulation. Several technological local production capabilities create additional challenges Some companies that manufacture DNA started collaboration to limit access to dangerous genes so that only authorized laboratories can obtain DNA of "about 60" lethal germs and toxins
Risks of pandemic prevention Efforts of pandemic prevention and related endeavors carry risks of triggering pandemics themselves. These risk include unwitting laboratory escape and accidents such as spillovers during field interventions like wildlife virus sampling, and misuse of its results due to e.g. insecure commercial sales of required equipment and/or materials and/or data. However, not engaging in any form of sampling also carries risks, as it could leave communities unprepared for future spillover events and unaware of future potential pathogens.
One approach to mitigate risks from pandemic prevention is to "maintain a database with hashes of deadly and dangerous sequences" which don't contain data with a potential for danger (depending on various factors) and also "can't be reverse-engineered to learn the dangerous original sequence if you don't already know it". This would theoretically enable checking sequences against a database of recorded pathogens without maintaining a database of deadly sequences. Another approach is not building such databases or not collecting dangerous sequences in the first place. A 2014 study proposed safer "alternatives to experiments with novel potential pandemic pathogens" than some of the current methods.
Pathogen detection and prediction
In a 2012 study it is claimed that "new mathematical modelling, diagnostic, communications, and informatics technologies can identify and report hitherto unknown microbes in other species, and thus new risk assessment approaches are needed to identify microbes most likely to cause human disease". The study investigates challenges in moving the global pandemic strategy from response to pre-emption. Some scientists are screening blood samples from wildlife for new viruses. The international Global Virome Project (GVP) aims to identify the causes of fatal new diseases before emergence in human hosts by genetically characterizing viruses found in wild animals. The project aims to enlist an international network of scientists to collect hundreds of thousands of viruses, map their genomes, characterize and risk-stratify them to identify which ones to pay attention to. However, some infectious disease experts have criticized the project as too broad and expensive due to limited global scientific and financial resources and because only a small percentage of the world's zoonotic viruses may cross into humans and pose a threat. They argue for prioritizing rapidly detecting diseases when they cross into humans and an improving the understanding of their mechanisms. A successful prevention of a pandemic from specific viruses may also require ensuring that it does not re-emerge – for instance by sustaining itself in domestic animals.
Pathogen detection mechanisms may allow the construction of an early warning system which could make use of artificial intelligence surveillance and outbreak investigation. Edward Rubin notes that after sufficient data has been gathered artificial intelligence could be used to identify common features and develop countermeasures and vaccines against whole categories of viruses. It might be possible to predict viral evolution using machine learning. In April 2020 it was reported that researchers developed a predictive algorithm which can show in visualizations how combinations of genetic mutations can make proteins highly effective or ineffective in organisms – including for viral evolution for viruses like SARS-CoV-2. In 2021, pathogen researchers reported the development of machine learning models for genome-based early detection and prioritization of high-risk potential zoonotic viruses in animals prior to spillover to humans which could be used for virus surveillance for (i.a.) measures of "early investigation and outbreak preparedness" and, according to the study, would have been capable of predicting SARS-CoV-2 as a high-risk strain without prior knowledge of zoonotic SARS-related coronaviruses.
An artificial "global immune system"-like technological system that includes pathogen detection may be able to substantially reduce the time required to take on a biothreat agent. A system of that sort would also include a network of well-trained epidemiologists who could be rapidly deployed to investigate and contain an outbreak.
Funding for the United States' PREDICT government research program that sought to identify animal pathogens that might infect humans and to prevent new pandemics was cut in 2019. Funding for United States' CDC programs that trained workers in outbreak detection and strengthened laboratory and emergency response systems in countries where disease risks are greatest to stop outbreaks at the source was cut by 80% in 2018.